Effectiveness of Care Measure






Start with Primary Care to Manage High-Risk Opioid Use

Learn how to improve your Health Care Effectiveness Data and Information Set (HEDIS®) rates. Review these quality measures on opioid use and other resources available to you.

| Quality measure | Percentage of m | nembers ages 18 | 3 and older who | |
|--|--|---|--|--|
| Use of opioids ¹ at high dosage (HDO) | Received prescribed opioids at a high dosage (average milligram morphine equivalent [MME] > 120 mg). Denominator: Two or more prescriptions on different dates of service with ≥ 5 total days covered by opioids during the measurement year (calendar year). | | | |
| Use of opioids from multiple providers (UOP) and pharmacies | Received prescribed opioids for \ge 15 total days during the measurement year (calendar year) ² from \ge 4 providers and pharmacies. | | | |
| Concurrent use of opioids and benzodiazepines | Had a concurrent use of prescription opioids and benzodiazepines. Beneficiaries with a cancer diagnosis or in hospice are excluded. | | | |
| | OPIOIDS | | BENZODIAZEPINES | |
| | Butorphanol Codeine Dihydrocodeine Fentanyl Hydrocodone Hydromorphone Levorphanol Meperidine | Methadone Morphine Opium Oxycodone Oxymorphone Pentazocine Tapentadol Tramadol | Alprazolam Chlordiazepoxide Clobazam Clonazepam Clorazepate Diazepam Estazolam | FlurazepamLorazepamMidazolamOxazepamQuazepamTemazepamTriazolam |
| Initiation and engagement of alcohol and other drug treatment (IET) | Had a new episode of alcohol or other drug (AOD) abuse or dependence who received the following (each measurement year, the quality measure collects data on new episodes of AOD abuse and dependence between January 1– November 14 of the calendar year): Initiation of AOD treatment – Percentage of members who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth, or medication treatment within 14 days of the diagnosis. Engagement of AOD treatment – Percentage of members who initiated treatment and who had two or more additional AOD services or medication treatment within 30 days of the initiation visit. | | | |



¹Excluded:

- · Members diagnosed with cancer or sickle cell disease.
- The opioid medication list excludes injectables; opioid cough and cold products; and single-agent and combination buprenorphine products used to treat opioid use disorder for medication assisted treatment (buprenorphine sublingual tablets, buprenorphine subcutaneous implant and all buprenorphine/naloxone combination products), and IONSYS® (fentanyl transdermal patch; for inpatient use only and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy [REMS]).

²The measurement year is the year data is collected for HEDIS. Example: HEDIS 2020 reporting year reflects services or data collected in the 2019 calendar year and reported in July 2020.

(continued)

Resources

Access the provider updates below in the Provider Library. After you log in at **provider.healthnet.com**, scroll to the bottom of the home page and select the Provider Library tile. Or, you can access the Provider Library directly at **providerlibrary.healthnetcalifornia.com.**

| Provider update | Distribution date | Update number |
|---|--------------------|------------------|
| Best Practices Prescribing and Managing Opioid Medications | May, 20, 2019 | 19-243 |
| Patient Education Tips for Opioid Therapy | July 26, 2019 | 19-431 |
| To Help You End Opioid Abuse: Preferred Drug List Changes Focus on Opioid Pain Medications | September 11, 2019 | 19-706 |
| Improve Treatment of OUD in Pregnancy with These Resources | October 21, 2019 | 19-816 |
| Refer Members to myStrength: An Additional Resource to Help with OUD and Substance Use | February 4, 2020 | 20-123 |



For questions or more information, email the Quality Improvement Department at cqi_dsm@healthnet.com.

Online articles and sites

| Title | URL |
|---|--|
| American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-5) | www.psychiatry.org/psychiatrists/practice/dsm/educational-resources |
| Assessing Benefits and Harms of Opioid Therapy | www.cdc.gov/drugoverdose/pdf/Assessing_Benefits_Harms_of_Opioid_Therapy-a.pdf |
| Benzodiazepines and Opioids | www.drugabuse.gov/drugs-abuse/opioids/benzodiazepines-opioids |
| Calculating Total Daily Dose of Opioids for Safer Dosage | www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf |
| Centers for Disease Control and Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain | www.cdc.gov/drugoverdose/prescribing/guideline.html |
| Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors | www.cms.gov/Medicare/Prescription-DrugCoverage/ PrescriptionDrugCovContra/Downloads/ Oral-MME-CFs-vFeb-2018.pdf |

Additional information

- **DEA X-Waiver** Go to the Providers Clinical Support System website at **pcssnow.org.** Attend free online webinars and get your certification.
- Buprenorphine Waiver Get a waiver to prescribe or dispense buprenorphine. To learn more, visit samhsa.gov/medication-assisted-treatment/training-materials-resources/apply-for-practitioner-waiver.

CalViva Health is a licensed health plan in California that provides services to Medi-Cal enrollees in Fresno, Kings and Madera counties. CalViva Health contracts with Health Net Community Solutions, Inc. to provide and arrange for network services. Health Net Community Solutions, Inc. is a subsidiary of Health Net, Inc. and Centene Corporation. Health Net is a registered service mark of Health Net, Inc. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly prohibited. If you have received this transmission in error, please notify the sender immediately by telephone or by return fax and destroy this transmission, along with any attachments.